Indivior shares plunge after US move and profit warning Pharma Indivior lowered its annual adjusted operating profit forecast and shares in the company plunged.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York Stock market Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Indivior plans primary US listing in another hit to London’s flagging equity market Not another one While the firm said it would look to maintain a secondary listing in the UK, the decision to shift its primary listing marks a big change for the company.